ArticleTherapeutic advances in musculoskeletal disease2022

Based on minimal clinically important difference values, a moderate dose of tanezumab may be a better option for treating hip or knee osteoarthritis: a meta-analysis of randomized controlled trials.

Di Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.